Cite
HARVARD Citation
Halker Singh, R. et al. (2019). Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia. pp. 52-60. [Online].